The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports
Abstract Background The clinical characteristics, therapy, and outcome of Fournier Gangrene (FG) in patients using sodium-glucose cotransporter-2 inhibitors (SGLT2i) were examined in this systematic review. Methods Without a publication year restriction, we searched PubMed, ScienceDirect, and Cochra...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Systematic Reviews |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13643-024-02746-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571929384452096 |
|---|---|
| author | Yufi Aulia Azmi Firas F. Alkaff Kevin Muliawan Soetanto Soetojo Wirjopranoto Maarten J. Postma Abdul Khairul Rizki Purba |
| author_facet | Yufi Aulia Azmi Firas F. Alkaff Kevin Muliawan Soetanto Soetojo Wirjopranoto Maarten J. Postma Abdul Khairul Rizki Purba |
| author_sort | Yufi Aulia Azmi |
| collection | DOAJ |
| description | Abstract Background The clinical characteristics, therapy, and outcome of Fournier Gangrene (FG) in patients using sodium-glucose cotransporter-2 inhibitors (SGLT2i) were examined in this systematic review. Methods Without a publication year restriction, we searched PubMed, ScienceDirect, and Cochrane. Additionally, we manually searched bibliographies using the terms "Fournier's gangrene" and "SGLT2 inhibitors." The requirements for inclusion were the English language case reports with specific patient data and FG patients with diabetes who were using SGLT2 medication. The risk of bias was analyzed utilizing the Joanna Briggs Institute checklists. Results A total of 78 studies were identified, and 14 of them were included in this review. The duration of SGLT2i use varied from 6 months to 6 years. The patients’ age varied from 34 to 72 years, with 10 studies including male participants only and patients with obesity. All studies have discontinued SGLT2i and replaced them with other anti-diabetic drugs. Therapy options included perianal ring block, insulin, rigid sigmoidoscopy, aggressive debridement, antibiotics, fluid resuscitation, incision, drainage, surgery, hyperbaric oxygen therapy, plastic surgery, and fasciocutaneous flaps. Seven studies reported patients discharged in the range of 9–51 days. Conclusions The incidence of FG following SGLT2i use is rare. Therapy was performed by replacing SGLT2i with other anti-diabetic drugs. The patient's outcome improved after treatment. |
| format | Article |
| id | doaj-art-60df0d737b184b19a9d5de043c061db5 |
| institution | Kabale University |
| issn | 2046-4053 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Systematic Reviews |
| spelling | doaj-art-60df0d737b184b19a9d5de043c061db52025-02-02T12:11:00ZengBMCSystematic Reviews2046-40532025-01-0114111010.1186/s13643-024-02746-3The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reportsYufi Aulia Azmi0Firas F. Alkaff1Kevin Muliawan Soetanto2Soetojo Wirjopranoto3Maarten J. Postma4Abdul Khairul Rizki Purba5Department of Health Sciences, University of Groningen, University Medical Center GroningenDivision of Pharmacology and Therapy, Department of Anatomy, Histology, and Pharmacology, Faculty of Medicine Universitas AirlanggaDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDepartment of Urology, Faculty of Medicine Universitas Airlangga – Dr. Soetomo General Academic HospitalDepartment of Health Sciences, University of Groningen, University Medical Center GroningenDepartment of Health Sciences, University of Groningen, University Medical Center GroningenAbstract Background The clinical characteristics, therapy, and outcome of Fournier Gangrene (FG) in patients using sodium-glucose cotransporter-2 inhibitors (SGLT2i) were examined in this systematic review. Methods Without a publication year restriction, we searched PubMed, ScienceDirect, and Cochrane. Additionally, we manually searched bibliographies using the terms "Fournier's gangrene" and "SGLT2 inhibitors." The requirements for inclusion were the English language case reports with specific patient data and FG patients with diabetes who were using SGLT2 medication. The risk of bias was analyzed utilizing the Joanna Briggs Institute checklists. Results A total of 78 studies were identified, and 14 of them were included in this review. The duration of SGLT2i use varied from 6 months to 6 years. The patients’ age varied from 34 to 72 years, with 10 studies including male participants only and patients with obesity. All studies have discontinued SGLT2i and replaced them with other anti-diabetic drugs. Therapy options included perianal ring block, insulin, rigid sigmoidoscopy, aggressive debridement, antibiotics, fluid resuscitation, incision, drainage, surgery, hyperbaric oxygen therapy, plastic surgery, and fasciocutaneous flaps. Seven studies reported patients discharged in the range of 9–51 days. Conclusions The incidence of FG following SGLT2i use is rare. Therapy was performed by replacing SGLT2i with other anti-diabetic drugs. The patient's outcome improved after treatment.https://doi.org/10.1186/s13643-024-02746-3Fournier’s gangreneSGLT2 inhibitorsClinical characteristicsSystematic review |
| spellingShingle | Yufi Aulia Azmi Firas F. Alkaff Kevin Muliawan Soetanto Soetojo Wirjopranoto Maarten J. Postma Abdul Khairul Rizki Purba The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports Systematic Reviews Fournier’s gangrene SGLT2 inhibitors Clinical characteristics Systematic review |
| title | The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports |
| title_full | The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports |
| title_fullStr | The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports |
| title_full_unstemmed | The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports |
| title_short | The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports |
| title_sort | impact of sodium glucose cotransporter 2 inhibitors on the incidence therapy and outcomes of fournier gangrene insights from a systematic review of case reports |
| topic | Fournier’s gangrene SGLT2 inhibitors Clinical characteristics Systematic review |
| url | https://doi.org/10.1186/s13643-024-02746-3 |
| work_keys_str_mv | AT yufiauliaazmi theimpactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT firasfalkaff theimpactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT kevinmuliawansoetanto theimpactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT soetojowirjopranoto theimpactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT maartenjpostma theimpactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT abdulkhairulrizkipurba theimpactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT yufiauliaazmi impactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT firasfalkaff impactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT kevinmuliawansoetanto impactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT soetojowirjopranoto impactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT maartenjpostma impactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports AT abdulkhairulrizkipurba impactofsodiumglucosecotransporter2inhibitorsontheincidencetherapyandoutcomesoffourniergangreneinsightsfromasystematicreviewofcasereports |